National Academies Press: OpenBook

An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program (2003)

Chapter: Appendix F Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1

« Previous: Appendix E Department of Defense Memorandum: Reintroduction of the Anthrax Vaccine Immunization Program
Suggested Citation:"Appendix F Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1." Institute of Medicine. 2003. An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program. Washington, DC: The National Academies Press. doi: 10.17226/10527.
×

Appendix F
Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1

FINDINGS

  • The CDC either has not developed, or has not communicated, a comprehensive plan for the CDC’s role in anthrax vaccine safety and efficacy research.

  • Despite the absence of a comprehensive plan, the CDC’s research program includes appropriate and well-conceived scientific projects that are generally responsive to the Congressional mandate.

  • The CDC’s research program also includes many particular projects that presently are quite underdeveloped or include unspecified elements.

  • Areas of potential collaboration between the CDC, DoD and NIH exist and should be more fully exploited, notably, for example the use of DoD databases such as the Defense Medical Surveillance System (DMSS).

  • The areas of potential deficit or concern can be remedied.

GENERAL RECOMMENDATIONS

  • The CDC should produce a comprehensive description of its research program, including statements of the goals of the program and how the plans now undertaken will meet those goals. In addition, the CDC should continue and complete development of the individual projects in the research program.

  • The CDC should consider engaging protocol design consultants representing broad scientific expertise who would provide immediate and direct consultation on specific technical matters of study design and execution.

  • The CDC should continue and strengthen collaboration with DoD and NIH wherever possible, including for example much more extensive use of DoD databases such as the Defense Medical Surveillance System (DMSS).

1  

These findings and recommendations appear in CDC Anthrax Vaccine Safety and Efficacy Research Program. Interim Report (Institute of Medicine, 2001; Washington, D.C.: National Academy Press). The complete report is available on the Internet at http://www.nap.edu/catalog/10157.html.

Suggested Citation:"Appendix F Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1." Institute of Medicine. 2003. An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program. Washington, DC: The National Academies Press. doi: 10.17226/10527.
×

PROJECT-SPECIFIC RECOMMENDATIONS

  • The committee recommends that, in the human clinical trial, the CDC should consider including a study group immunized at the start of the series (time zero), and one and six months later, followed by placebo, in order to assess adequacy of a simplified three-dose regimen in the development of immediate and long-term immunity to anthrax.

  • The committee recommends careful selection of statistical methodologies, as certain techniques including intent-to-treat analysis may be less appropriate in developing conclusions for what will eventually be a military application than they would be for general civilian vaccine development.

  • The committee recommends that the CDC consider, in addition to the proposed clinical trial, prospectively designed pharmacoepidemiologic study of military vaccine recipients with both active surveillance and historical data from DMSS for moderate and severe adverse events in order to assess sex or gender and perhaps other risk factors for adverse events among military personnel receiving the anthrax vaccine.

  • The committee recommends that the CDC consider both the addition of a passive antibody transfer study, and that the animal trial dose ranging study design include a more gradual dilution series.

  • The committee recommends that the use of microarrays receive further critical attention and precise evaluation of what information will be gleaned and how it will be interpreted and applied to anthrax vaccine recipients.

  • The committee recommends that the CDC consider expanding the design phase of the KAB study of military personnel regarding the anthrax vaccine to include cognitive and psychometric tests and a pilot survey in order to design both the educational interventions and the survey that will relate to them, in order to refine the sampling plan.

  • The committee recommends that the CDC consider expanding the design phase of the KAB study of military vaccine providers regarding VAERS reporting to include cognitive and psychometric tests and a pilot survey, in order to design both the educational interventions and the survey that will relate to them and possibly reduce the number of subjects.

  • The committee recommends that the CDC consider including a study of the KAB of health care providers regarding the anthrax vaccine in the study now designed to assess only KAB on VAERS reporting.

  • The committee recommends that the CDC make use of independent sources of information concerning vaccine adverse reactions in the military, such as the DMSS, when assessing any monitoring of, or modification to, VAERS reporting practices and VAERS analysis.

  • The committee recommends that the CDC consider including additional items with the SF-36 specific to adverse events possibly associated with immunization, and clearly indicate how the use of the SF-36 will be included in the protocol.

Suggested Citation:"Appendix F Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1." Institute of Medicine. 2003. An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program. Washington, DC: The National Academies Press. doi: 10.17226/10527.
×
Page 153
Suggested Citation:"Appendix F Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1." Institute of Medicine. 2003. An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program. Washington, DC: The National Academies Press. doi: 10.17226/10527.
×
Page 154
Next: Appendix G Institute of Medicine: The Anthrax Vaccine: Is It Safe? Does It Work? Findings and Recommendations1 »
An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program Get This Book
×
Buy Paperback | $45.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

In 1998, the Department of Defense (DoD) began a program of mandatory immunization against anthrax for all military personnel. As the program proceeded, however, some military personnel and their families raised concerns about the safety and efficacy of the anthrax vaccine. Acknowledging both the need to protect military personnel and the concerns about the anthrax vaccine, congress directed the Centers for Disease Control and Prevention (CDC) to carry out a research program on its safety and efficacy. To assist in the development of this program, CDC requested the Institute of Medicine (IOM) to convene a committee to review the completeness and appropriateness of the research program. In An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program, the committee makes an overall assessment of the CDD research plan and reviews the specific studies proposed by CDC in the three areas of efficacy, safety and acceptability. The committee also notes additional research needs that became evident following the bioterrorist events of 2001 and makes recommendations about the leadership of the research program.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!